stockrowADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
Follow ADMA
Alert me
ADMA Biologics Inc (ADMA) P/S ratio
As of 5 November 2026, ADMA Biologics Inc (ADMA) trades at a P/S ratio of 5.7×. Over the past ten years it has ranged from 2.1× (October 2021) to 18.5× (July 2015); the current reading is higher than 47% of that period. That is below the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 8.5× | (9.11%) |
| FY2024 | 9.4× | 137.50% |
| FY2023 | 3.9× | (20.59%) |
| FY2022 | 5.0× | 104.41% |
| FY2021 | 2.4× | (38.89%) |
| FY2020 | 4.0× | (46.28%) |
| FY2019 | 7.4× | 16.49% |
| FY2018 | 6.4× | 91.54% |
| FY2017 | 3.3× | (41.52%) |
| FY2016 | 5.7× | (51.51%) |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 4.3× | 15.89% |
| Jun 2026 | 3.7× | (10.61%) |
| Mar 2026 | 4.2× | (51.04%) |
| Dec 2025 | 8.5× | 19.00% |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PHVS Pharvaris N.V. compare | n/m |
| VERA Vera Therapeutics, Inc. compare | n/m |
| BHVN Biohaven Ltd. compare | 2.1× |
| ADMA ADMA Biologics Inc | 5.7× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.7× |
| VCEL Vericel Corporation compare | 8.1× |
| PVLA Palvella Therapeutics, Inc. compare | 54.1× |
| IMNM Immunome, Inc. compare | 162× |
| CLDX Celldex Therapeutics, Inc. compare | 2,498× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on ADMA
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement